Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
: ~* A4 _. S2 Q1 P$ ]; Q1 R( [NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 * }" l, o2 t ?# M" y
+ Author Affiliations
! `; y. F9 P1 a' n. g2 x7 u! X4 f, u6 a& ?, K4 L, v
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan * K4 G+ S% o3 h9 V$ ~4 O
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan " h% l1 A9 b4 a& p
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan - k1 G" B. s& R: Q" n0 r* {- S
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
: [4 {7 G- d s7 x5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
1 d: r8 m% P% R7 u( [( }9 i0 |6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan % F( K v( G7 [1 b. J. M
7Kinki University School of Medicine, Osaka 589-8511, Japan . j$ h2 F7 h6 }: I! T
8Izumi Municipal Hospital, Osaka 594-0071, Japan , E- W2 \ }1 q$ ?/ | D* l3 Y
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
) I3 w" @7 R& l0 ^3 d# N1 U DCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp % `& p3 ~7 q" D6 F }
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. & o& W! D' m# q# g
* u, K$ a- @5 _. m |